The success of a scientist will depend on their manufacturing of scientific papers and the influence issue of the journal by which they publish. As a result of most main scientific journals are printed in English, success is said to publishing on this language. At present, 98% of publications in science are written in English, together with researchers from English as a International Language (EFL) international locations.
Colombia is among the many international locations with the bottom English proficiency on this planet. Thus, understanding the disadvantages that Colombians face in publishing is essential to decreasing international inequality in science. This paper quantifies the disadvantages that end result from the language hegemony in scientific publishing by analyzing the extra prices that speaking in English creates within the manufacturing of articles.
| Positive control tissue section for each individua | |||
| Control-Slides-for-each-antibody | |||
| ASAP1 antibody Antibody | |||
| DF8746 | |||
| CD11b Antibody Antibody | |||
| ABD2911 | |||
| anti- Antibody^Polyclonal antibody control antibody | |||
| LSMab09882 | |||
| ARHGDIA Antibody / RHOGDI Antibody | |||
| F54788-0.08ML | |||
It was recognized that greater than 90% of the scientific articles printed by Colombian researchers are in English, and that publishing in a second language creates extra monetary prices to Colombian doctoral college students and leads to issues with studying comprehension, writing ease and time, and nervousness. Rejection or revision of their articles due to the English grammar was reported by 43.5% of the doctoral college students, and 33% elected to not attend worldwide conferences and conferences because of the necessary use of English in oral shows.
Lastly, among the many translation/enhancing providers reviewed, the fee per article is between one-quarter and one-half of a doctoral month-to-month wage in Colombia. Of specific be aware, we recognized a optimistic correlation between English proficiency and better socioeconomic origin of the researcher. Total, this examine reveals the unfavourable penalties of hegemony of English that preserves the worldwide hole in science.
Though having a standard language is necessary for science communication, producing multilinguistic options would promote variety whereas conserving a communication channel. Such an effort ought to come from totally different actors and mustn’t fall solely on EFL researchers.
| Custom Antibody titration by ELISA up to 2 rabbits and 1 bleed | |||
| ELISA-1 | |||
| Beta2-Microglobulin ELISA kit ELISA Kit | |||
| LF-EK60047 | |||
| Chicken thrombomodulin,TM ELISA KIT ELISA | |||
| QY-E80092 | |||
Studying Analytics to Assess Beliefs about Science: Evolution of Experience as Seen by way of Organic Inquiry
Epistemological beliefs about science (EBAS) or beliefs in regards to the nature of science information, and the way that information is generated throughout inquiry, are an important but troublesome to evaluate element of science literacy. Leveraging studying analytics to seize and analyze pupil practices in simulated or game-based genuine science actions is a possible avenue for assessing EBAS. Our earlier work characterised inquiry practices of consultants and novices engaged in simulated genuine science inquiry and steered that practices might replicate EBAS.
Right here, we prolong our prior qualitative work to quantitatively study variations in practices and EBAS between non-science majors, biology majors, and biology graduates. We noticed that inquiry practices of non-science majors and biology graduates have been much like the novice and professional practices, respectively, in our prior work.
Nonetheless, biology majors typically appeared to behave like their undergraduate friends (e.g., performing fewer planning actions) however different occasions have been extra much like biology graduates (e.g., performing complicated investigations). We famous that cognitive constructs like metacognition have been additionally necessary for understanding which practices have been most definitely to be reflective of EBAS.
This work advances the right way to assess EBAS utilizing studying analytics and raises questions relating to the event of cognitive processes like EBAS amongst aspiring biologists. The targets of the workshop organized by Piotr Marszalek and Andres Oberhauser that occurred between 29 August and 1 September 2019 at Duke College have been to carry collectively main consultants and junior researchers to overview previous accomplishments, latest advances and limitations within the single-molecule drive spectroscopy subject, which examines nanomechanical forces in numerous organic processes and pathologies. Talks have been organized into 4 periods, and two in-depth roundtable dialogue periods have been held.
| Custom Antibody titration by ELISA up to 2 rabbits and 1 bleed | |||
| Alpha Diagnostics | |||
| Beta2-Microglobulin ELISA kit ELISA Kit | |||
| Abfrontier | |||
| Chicken thrombomodulin,TM ELISA KIT ELISA | |||
| Qayee Biotechnology | |||
Re-thinking the principle targets of organic sciences: is it potential to construct new information with out elementary analysis?
Relationships between collective scientific information and nation’s financial prosperity and competitiveness have been described. Therefore, interactions between business and tutorial establishments is seen as a strategy to valorize this information at social and financial ranges.
The flexibility to translate scientific information in social and financial advantages is now receiving many of the funding for public analysis. Nonetheless, and regardless of the evident long-term advantages of funding utilized science, drastic discount of funds for elementary analysis might ultimately result in the other consequence. This text is protected by copyright. All rights reserved.
| Custom Antibody titration by ELISA up to 2 rabbits and 1 bleed | |
| ELISA-1 | Alpha Diagnostics |
| Beta2-Microglobulin ELISA kit ELISA Kit | |
| LF-EK60047 | Abfrontier |
| Chicken thrombomodulin,TM ELISA KIT ELISA | |
| QY-E80092 | Qayee Biotechnology |
| Oxycodone ELISA | |
| EK7130 | BosterBio |
| Amphiphysin ELISA | |
| LF-EK0189 | Abfrontier |
Growing old is related to lack of operate throughout organ methods, contributing to systemic frailty. Lack of skeletal muscle mass and performance, particularly, is a serious supply of frailty in older adults, severely impacting high quality of life. Some lack of muscle mass and power with getting old is inevitable, and sarcopenia, the extreme lack of muscle mass with getting old, is frequent. Sarcopenia is decided partially by genetics however may be modified by way of life decisions.
AAV1-Luc Control Virus |
|||
| AAV-321 | Cell Biolabs | 50 ?L | 1221.6 EUR |
|
Description: Luciferase control virus of AAV serotype 1. |
|||
AAV3-Luc Control Virus |
|||
| AAV-323 | Cell Biolabs | 50 ?L | 1221.6 EUR |
|
Description: Luciferase control virus of AAV serotype 3. |
|||
AAV4-Luc Control Virus |
|||
| AAV-324 | Cell Biolabs | 50 ?L | 1221.6 EUR |
|
Description: Luciferase control virus of AAV serotype 4. |
|||
AAV5-Luc Control Virus |
|||
| AAV-325 | Cell Biolabs | 50 ?L | 1221.6 EUR |
|
Description: Luciferase control virus of AAV serotype 5. |
|||
AAV6-Luc Control Virus |
|||
| AAV-326 | Cell Biolabs | 50 ?L | 1221.6 EUR |
|
Description: Luciferase control virus of AAV serotype 6. |
|||
Lenti-hTERT Antisense virus |
|||
| G201 | ABM | 10 ml | 882 EUR |
Lenti-hTERT-Neo Virus |
|||
| G204 | ABM | 10 ml | 973.2 EUR |
Lenti-Myc T58A Virus |
|||
| G217 | ABM | 10 ml | 973.2 EUR |
Lenti-p53 siRNA Virus |
|||
| G219 | ABM | 10 ml | 973.2 EUR |
Lenti-Ras V12 Virus |
|||
| G221 | ABM | 10 ml | 973.2 EUR |
Lenti-Rb siRNA Virus |
|||
| G223 | ABM | 10 ml | 973.2 EUR |
NF-κB Reporter (Luc) - HCT116 Cell Line |
|||
| 60623 | BPS Bioscience | 2 vials | 1095 EUR |
|
Description: NF-B luciferase reporter construct is stably integrated into the genome of HCT-116 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase/HCT-116 cell line is suitable for monitoring the activity of NF-κB signaling in response to stimulants such as the cytokines TNF and IL-1β, pathogen-associated molecular pattern (PAMP) (i.e. flagellin) or endogenous damage-associated molecular pattern (DAMP) molecules (i.e. NOD1 ligand) (see application references). It is also suitable for establishing cell-based screens for inhibitors that target specific NF-κB stimulating molecules. This cell line can be further modified to allow investigation of downstream NF-κB activities as a result of targeted genetic mutation(s). |
|||
Foxp3 Reporter (Luc) - Jurkat Recombinant Cell Line |
|||
| 60628 | BPS Bioscience | 2 vials | 7645 EUR |
|
Description: Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter. |
|||
NF-κB reporter (Luc) - HEK293 Cell line |
|||
| 60650 | BPS Bioscience | 2 vials | 1365 EUR |
|
Description: The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17. |
|||
STAT5 Reporter (Luc) - Ba/F3 Cell line |
|||
| 79772 | BPS Bioscience | 2 vials | 2275 EUR |
|
Description: The STAT5 Reporter (Luc)-Ba/F3 cell line is designed for monitoring STAT5 signal transduction pathways. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by cytokines or growth factors, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin) |
|||
| 79800-P | BPS Bioscience | 2 vials | 3730 EUR |
|
Description: The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
IRF Reporter (Luc) - THP-1 Cell line |
|||
| 79858 | BPS Bioscience | 2 vials | 1810 EUR |
|
Description: The Interferon Regulatory Factor (IRF) reporter (Luc)-THP-1 cell line is designed to study the activation and signaling of Cytosolic DNA Sensors (CDS) in human monocytic cell line THP-1. It contains a firefly luciferase gene driven by multimerized ISRE (Interferon Stimulated Response Element) located upstream of the minimal TATA promoter. _x000D_The cGAS-STING pathway acts to detect cytosolic DNA and induce an immune response. Briefly, upon binding DNA, the protein cGAS (cyclic GMP-AMP Synthase) triggers reaction of GTP and ATP to form cGAMP. cGAMP binds to STING (Stimulator of Interferon Genes) which triggers phosphorylation of IRF3 via TBK1. IRF3 can then bind to interferon-stimulated responsive elements (ISRE) in the nucleus and leads to IFN-α/β production. The IRF reporter (Luc)-THP-1 cell line is highly responsive to STING and CDS ligands. |
|||
Bald Lentiviral Pseudovirion (Luc-eGFP Dual Reporter) |
|||
| 79988 | BPS Bioscience | 500 µl x 2 | 795 EUR |
|
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) as the reporters, driven by a CMV promoter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_ |
|||
Lenti-Bmi1 Virus, High Titer |
|||
| LV608 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-CDK4 Virus, High Titer |
|||
| LV609 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-hTERT Virus, High Titer |
|||
| LV615 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-EF1α-hTERT Virus |
|||
| G706 | ABM | 10 ml | 1094.4 EUR |
PAI-1 Reporter (Luc) - Mv1 Lu Cell Line |
|||
| 60544 | BPS Bioscience | 2 vials | 3595 EUR |
|
Description: PAI-1 Reporter (Luc)-Mv1 Lu cell line is designed for monitoring transforming growth factor β (TGF-β)-induced plasminogen activator inhibitor-1 (PAI-1) expression. Transforming growth factor-β (TGF-β) is a potent regulator of cellular differentiation, proliferation, migration, and protein expression._x000D__x000D_PAI-1 Reporter (Luc) -Mv1 Lu cell line contains a firefly luciferase gene under the control of PAI-1 responsive elements stably integrated into Mv1 Lu (NBL-7) cells, showing TGF-β pathway response. This cell line is validated for the TGF-β response to the induction of PAI-1 gene expression through luciferase activity. _x000D_ |
|||
NF-κB Reporter (Luc) - CHO-K1 Cell Line |
|||
| 60622 | BPS Bioscience | 2 vials | 1095 EUR |
|
Description: An NF-κB luciferase reporter construct is stably integrated into the genome of CHO-K1 cells. The firefly luciferase gene is controlled by the NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase / CHO-K1 cell line is suitable for monitoring the activity of NF-κB transcription factor through luminescence readout.). This cell line responds to human cytokine IL-1β, responds moderately to human TNF, and does not respond to human IFN-λ (2 µg/ml). Reducing the amount of serum during incubation period may increase the sensitivity to cytokines. Since CHO-K1 cells do not express endogenous human proteins, this cell line provides an excellent platform to enable exogenous expression of a protein of interest to study its downstream effect on NF-κB signaling. |
|||
NF-κB Reporter (Luc) - A549 Stable Cell Line |
|||
| 60625 | BPS Bioscience | 2 vials | 1915 EUR |
|
Description: NF-κB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. |
|||
NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line |
|||
| 60651 | BPS Bioscience | 2 vials | 2340 EUR |
|
Description: NF-κB luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by 4 copies of NF-kB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. |
|||
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78172-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
|||
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78172-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
|||
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78204-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78204-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78205-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
|||
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78205-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
|||
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78206-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
|||
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78206-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
|||
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78215-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78215-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
|||
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78614-1 | BPS Bioscience | 100 µl | 860 EUR |
|
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78614-2 | BPS Bioscience | 500 µl x 2 | 4320 EUR |
|
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
NF-κB reporter (Luc) - NIH/3T3 Cell line |
|||
| 79469 | BPS Bioscience | 2 vials | 1900 EUR |
|
Description: The NF-κB reporter (Luc)-NIH/3T3 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
NF- κB Reporter (Luc) - THP-1 Cell Line |
|||
| 79645 | BPS Bioscience | 2 vials | 1900 EUR |
|
Description: The NF-κB reporter (Luc)-THP-1 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
STAT5 Reporter (Luc)- U937 Cell Line (GM-CSF) |
|||
| 79941 | BPS Bioscience | 2 vials | 1980 EUR |
|
Description: The STAT5 Reporter (Luc)-U937 cell line is designed for monitoring STAT5 signal transduction pathway in the U937 cell line. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by GM-CSF, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
NF- κB Reporter (Luc) - Raw 264.7 Cell line |
|||
| 79978 | BPS Bioscience | 2 vials | 2045 EUR |
|
Description: The NF-κB reporter (Luc)-Raw 264.7 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
AACP 3'UTR Luciferase Stable Cell Line |
|||
| TU000012 | ABM | 1.0 ml | 2799.6 EUR |
AACP 3'UTR GFP Stable Cell Line |
|||
| TU050012 | ABM | 1.0 ml | 2799.6 EUR |
Steady-Luc Firefly HTS Assay Kit (10x100 ml) |
|||
| 30028-3 | Biotium | 1KIT | 3774 EUR |
|
Description: Minimum order quantity: 1 unit of 1KIT |
|||
Human BM88 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10021VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10022VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10023VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Rat NSE Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10024VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse MBP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10026VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human Opsin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10027VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human Insulin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10028VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human LCK Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10032VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Rat Nestin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10034VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human Nestin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10035VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse ALBP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10036VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human NGN3 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10037VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human PDX1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10039VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1003VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10040VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human MAP2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10047VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human FABP7 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10048VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human ACTC Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10049VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human B29 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1004VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10050VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human GFAP Differentiation Reporter (pRedZeo, Virus) |
|||
| SR10051VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse B29 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1005VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human NKX2.5 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10067VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse CD8 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1006VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse CD68 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1008VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human CD2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1009VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Oct4 CR4-pGreenFire Response Reporter (virus) |
|||
| SR20070-VA-1 | SBI | >2 x 10^6 IFUs | 882 EUR |
Mouse Actc Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10010VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10012VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10013VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse SM22a Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10014VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human GFAP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10015VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse GFAP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10016VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human CD11b Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10017VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10018VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1001VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse CD44 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10020VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line |
|||
| TR860A-1 | SBI | >2 x 10^6 cells | 3915.6 EUR |
Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway) |
|||
| 60520 | BPS Bioscience | 2 vials | 2175 EUR |
|
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β-catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter. |
|||
GITR / NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line |
|||
| 60546 | BPS Bioscience | 2 vials | 10175 EUR |
|
Description: This cell line expresses a surface human GITR (glucocorticoid-induced TNFR family related gene; TNFRSF18; CD357) and an NF-κB luciferase reporter construct that are stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. The cells have been validated using purified human GITRL and anti-GITR neutralizing antibody. |
|||
CD40/NF-κB Reporter (Luc) - HEK293 Stable Cell Line |
|||
| 60626 | BPS Bioscience | 2 vials | 6825 EUR |
|
Description: Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene. _x000D_ |
|||
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78028-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
|||
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78028-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
|||
GLP-1R/CRE (Luc) Reporter - HEK293 Recombinant Cell Line |
|||
| 78176 | BPS Bioscience | 2 vials | 10105 EUR |
|
Description: Recombinant HEK293 cells expressing firefly luciferase gene under the control of cAMP response element (CRE) with constitutive expression of human GLP-1R (Glucagon-like peptide 1 receptor; accession number BC113493)._x000D_GLP-1R, a member of the class B family of G protein-coupled receptors (GPCRs) primarily found in pancreatic β cells, is activated by a peptide hormone, glucagon-like peptide 1 (GLP-1) that is secreted from intestinal L-cells after nutrient ingestion. GLP-1R plays an important role in controlling blood sugar level by enhancing glucose-stimulated insulin secretion, so various research efforts have focused on the regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to diabetes. |
|||
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78348-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
|||
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78348-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
|||
Lenti-Myc T58A Virus, High Titer |
|||
| LV618 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-p53 siRNA Virus, High Titer |
|||
| LV619 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-Ras V12 Virus, High Titer |
|||
| LV620 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-Rb siRNA Virus, High Titer |
|||
| LV621 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-hTERT-Neo Virus, High Titer |
|||
| LV622 | ABM | 5 x 20 ul | 1825.2 EUR |
Lenti-HPV-16 E6/E7 Virus |
|||
| G268 | ABM | 10 ml | 882 EUR |
GR-GAL4 Reporter (Luc)-HEK293 Cell Line (Glucocorticoid Receptor Pathway) |
|||
| 60655 | BPS Bioscience | 2 vials | 2275 EUR |
|
Description: The Glucocorticoid Receptor Pathway GAL4 Reporter (Luc) - HEK293 Cell Line contains a_x000D_firefly luciferase gene under the control of glucocorticoid receptor ligand binding domain that is_x000D_fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR) stably integrated into_x000D_HEK293 cells. This fusion construct activates firefly luciferase expression under the control of a_x000D_multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of_x000D_glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual_x000D_transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell_x000D_line is validated for response to stimulation of dexamethasone and to the treatment with_x000D_mifepristone, an inhibitor of the glucocorticoid signaling pathway. |
|||
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78112-1 | BPS Bioscience | 100 µl | 875 EUR |
|
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78112-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR |
|
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78218-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78218-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility. |
|||
GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway) |
|||
| 79041 | BPS Bioscience | 2 vials | 1810 EUR |
|
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene. |
|||
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) |
|||
| 79982-1 | BPS Bioscience | 100 µl | 1075 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_ |
|||
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) |
|||
| 79982-2 | BPS Bioscience | 500 µl x 2 | 8110 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_ |
|||
Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10025VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human SPP-1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1002VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10038VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10041VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1007VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human MLC-2v Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10011VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro |
|||
| SR10015VA-P | SBI | >2 x 10^6 IFUs | 906 EUR |
Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10019VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Lenti-EF1α-hTERT Virus, High Titer |
|||
| LV616 | ABM | 5 x 20 ul | 2068.8 EUR |
Lenti-CMV-hTERT-GFP-2A-Puro Virus |
|||
| LV623 | ABM | 10 ml | 1270.8 EUR |
Lenti-CMV-hTERT-RFP-2A-Puro Virus |
|||
| LV625 | ABM | 10 ml | 1270.8 EUR |
AACP Recombinant Protein (Human) |
|||
| RP045415 | ABM | 100 ug | Ask for price |
CRE/CREB Reporter (Luc) - HEK293 Cell Line (cAMP/PKA Signaling Pathway) |
|||
| 60515 | BPS Bioscience | 2 vials | 2070 EUR |
|
Description: The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line is designed for monitoring the activity of the cAMP/ PKA signaling pathway. The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into HEK293 cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase. |
|||
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78142-1 | BPS Bioscience | 100 µl | 860 EUR |
|
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78142-2 | BPS Bioscience | 500 µl x 2 | 4320 EUR |
|
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78143-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_ |
|||
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78143-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_ |
|||
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78144-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_ |
|||
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78144-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_ |
|||
CRE/CREB Reporter (Luc) - Jurkat Cell Line (cAMP/PKA Signaling Pathway) |
|||
| 79636 | BPS Bioscience | 2 vials | 1810 EUR |
|
Description: The CRE/CREB Reporter (Luc) - Jurkat Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into Jurkat cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase. This cell line is validated for response to stimulation by Forskolin. |
|||
Human E-Cadherin, CDH1 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10070VA-1 | SBI | >2 x 10^6 IFUs | 906 EUR |
Sox2 SRR2-pGreenFire Response Reporter, pre-packaged virus |
|||
| SR20071-VA-1 | SBI | >2 x 10^6 IFUs | 882 EUR |
AACP sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0014404 | ABM | 1.0 ug DNA | 184.8 EUR |
pLL-CMV-GFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL100VA-1 | SBI | >2x10^6 IFUs | 810 EUR |
pLL-CMV-GFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL105VA-1 | SBI | >2x10^6 IFUs | 810 EUR |
pLL-CMV-RFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL110VA-1 | SBI | >2x10^6 IFUs | 810 EUR |
pLL-CMV-RFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL115VA-1 | SBI | >2x10^6 IFUs | 810 EUR |
pLL-CMV-BFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL120VA-1 | SBI | >2x10^6 IFUs | 810 EUR |
The pathophysiologic underpinnings of sarcopenia are complicated and multifactorial. On this overview, the causes of sarcopenia are surveyed on the methods, cell, subcellular, and molecular ranges with emphasis on the interaction between these numerous causes of this degenerative illness course of. Twenty years in the past, halogen bonding attracted appreciable consideration as a brand new sort of non-covalent interplay and has now emerged as an necessary supramolecular instrument for crystal engineering, demonstrating its means to self-assemble low affinity entities.